Format

Send to

Choose Destination
Blood. 2008 Feb 15;111(4):2378-81. Epub 2007 Nov 2.

In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib.

Author information

1
Department of Haematology, Hammersmith Hospitals Trust and Imperial College London, London, United Kingdom.

Abstract

We sought kinase domain (KD) mutations at the start of treatment with dasatinib in 46 chronic myeloid leukemia (CML) patients resistant to or intolerant of imatinib. We identified BCR-ABL mutant subclones in 12 (26%) cases and used pyrosequencing to estimate subsequent changes in their relative size after starting dasatinib. Four patients lost their mutations, which remained undetectable, 3 patients retained the original mutation or lost it only transiently, 3 lost their original mutations but acquired a new mutation (F317L), and 2 developed another mutation (T315I) in addition to the original mutation within the same subclone. This study shows that expansion of a mutant Ph-positive clone that responds initially to a second generation tyrosine kinase inhibitor may be due either to late acquisition of a second mutation in the originally mutated clone, such as the T315I, or to acquisition of a completely new mutant clone, such as F317L.

PMID:
17982022
DOI:
10.1182/blood-2007-06-096396
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center